Zealand Pharma AS (OCSE:ZEAL)
kr 730 0 (0%) Market Cap: 51.57 Bil Enterprise Value: 43.49 Bil PE Ratio: 0 PB Ratio: 5.83 GF Score: 67/100

Zealand Pharma A/S - Special Call Transcript

Mar 21, 2019 / 03:00PM GMT
Release Date Price: kr117.6 (+3.89%)
Operator

Good afternoon, ladies and gentlemen, and thank you for standing by, and welcome to today's Zealand Pharma R&D and Business Update Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, Thursday, the 21st of March 2019.

I would now like to hand the conference over to your speaker today, Adam Steensberg. Please go ahead, sir.

Adam Steensberg;S;Interim CEO
Zealand Pharma A;Executive VP and Chief Medical & Development Officer

/- -

Thank you, Annette, and welcome, everyone. It's great to have you join this exciting R&D update. Joining me on today's call is Andrew Parker, our Chief Science Officer.

Page 2 outlines what we will cover during today's call. We have spent significant time talking about our late stage program, but today is a great opportunity to discuss our research and preclinical programs. I will start by providing highlights from our recently signed collaboration with Alexion Pharmaceuticals, with whom we are thrilled to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot